Bacillus anthracis secretes two bipartite toxins thought to be involved in anthrax pathogenesis and resulting death of the host. The current model for intoxication is that protective antigen (PA) toxin subunits bind a single group of cell-surface anthrax toxin receptors (ATRs), encoded by the tumor endothelial marker 8 (TEM8) gene. The ATR͞TEM8-PA interaction is mediated by the receptor's extracellular domain related to von Willebrand factor type A or integrin inserted domains (VWA͞I domains). A metal ion-dependent adhesion site (MIDAS) located within this domain of the ATR͞TEM8 protein chelates a divalent cation critical for PA binding. In this report, we identify a second PA receptor encoded by capillary morphogenesis gene 2 (CMG2), which has 60% amino acid identity to ATR͞TEM8 within the VWA͞I domain, as well as a conserved MIDAS motif. A recombinant CMG2 protein bound PA and mediated toxin internalization when expressed on receptor-deficient cells. Binding between the CMG2 VWA͞I domain and PA was shown to be direct and metal-dependent, although the cation specificity of this interaction is different than that observed with ATR͞TEM8. Northern blot analysis revealed that CMG2 is widely expressed in human tissues, indicating that this receptor is likely to be relevant for disease pathogenesis. Finally, a soluble version of the CMG2 VWA͞I domain inhibited intoxication of cells expressing endogenous toxin receptors when it was added to PA at a 3:1 ratio. These studies distinguish CMG2 as a second anthrax toxin receptor and identify a potent antitoxin that may prove useful for the treatment of anthrax.
Bacillus anthracis secretes two bipartite toxins thought to be involved in anthrax pathogenesis and resulting death of the host. The current model for intoxication is that protective antigen (PA) toxin subunits bind a single group of cell-surface anthrax toxin receptors (ATRs), encoded by the tumor endothelial marker 8 (TEM8) gene. The ATR͞TEM8-PA interaction is mediated by the receptor's extracellular domain related to von Willebrand factor type A or integrin inserted domains (VWA͞I domains). A metal ion-dependent adhesion site (MIDAS) located within this domain of the ATR͞TEM8 protein chelates a divalent cation critical for PA binding. In this report, we identify a second PA receptor encoded by capillary morphogenesis gene 2 (CMG2), which has 60% amino acid identity to ATR͞TEM8 within the VWA͞I domain, as well as a conserved MIDAS motif. A recombinant CMG2 protein bound PA and mediated toxin internalization when expressed on receptor-deficient cells. Binding between the CMG2 VWA͞I domain and PA was shown to be direct and metal-dependent, although the cation specificity of this interaction is different than that observed with ATR͞TEM8. Northern blot analysis revealed that CMG2 is widely expressed in human tissues, indicating that this receptor is likely to be relevant for disease pathogenesis. Finally, a soluble version of the CMG2 VWA͞I domain inhibited intoxication of cells expressing endogenous toxin receptors when it was added to PA at a 3:1 ratio. These studies distinguish CMG2 as a second anthrax toxin receptor and identify a potent antitoxin that may prove useful for the treatment of anthrax. A nthrax is caused by the spore-forming organism Bacillus anthracis. Recently, this disease attracted considerable attention as a major bioterrorist threat because the deliberate mailing of B. anthracis spores via the U.S. postal system resulted in the deaths of five people (1) . This organism secretes two AB-type exotoxins, edema toxin and lethal toxin, that are both thought to play pivotal roles in disease pathogenesis. These toxins share a receptor-binding, B-moiety, protective antigen (PA), but differ in their alternative catalytic A-moieties. The A-moiety of edema toxin, termed edema factor, is a calmodulin-dependent adenylate cyclase that converts intracellular ATP to cAMP. By contrast, lethal toxin contains lethal factor (LF), a zinc-dependent metalloproteinase that cleaves and inactivates most mitogen-activated protein kinase kinases and causes murine macrophage lysis by an unknown mechanism (reviewed in ref. 2) .
The first step in intoxication involves binding of an 83-kDa form of PA (PA83) to a cell-surface receptor, where it subsequently undergoes a cleavage by furin to generate a 63-kDa PA subunit (PA63) (3). PA63 spontaneously assembles into a heptameric ring, or prepore, that can bind up to three molecules of either edema factor or LF (4) . The oligomerization of PA63 on cell surfaces is associated with receptor clustering and toxin complex internalization (3, 5) . After endocytosis, the toxin complex is trafficked to an acidic endosomal compartment where low pH-induced conformational changes in the PA heptamer lead to its insertion in the endosomal membrane and translocation of edema factor and LF into the cytoplasm (6) (7) (8) .
A human cell-surface receptor, anthrax toxin receptor (ATR), which binds directly to PA and supports cellular intoxication, was recently identified (9) . ATR is encoded by the tumor endothelial marker 8 (TEM8) gene, which is expressed in a wide variety of tissues [see National Center for Biotechnology Information (NCBI) UniGene cluster Hs.8966; www.ncbi.nlm.nih.gov͞ entrez͞query.fcgi?dbϭunigene] but at increased levels in colon tumor vasculature (10) . Expression of the mouse homolog of TEM8 is up-regulated in the vasculature of the developing mouse embryo (11) , suggesting that the product(s) of this gene may have some role in neovascularization. However, the physiological function of ATR͞TEM8 is not yet known.
At least three different ATR͞TEM8 protein isoforms have been described that are produced from alternatively spliced mRNA transcripts (splice variants 1-3, or sv1-3). ATR͞TEM8 sv1 and sv2 (GenBank accession nos. NP115584 and NP444262, respectively) function as ATRs, whereas the putative secreted sv3 protein (GenBank accession no. NP060623) does not (refs. 9 and 12; H.M.S. and J.A.T.Y., unpublished data). ATR͞TEM8 sv1 and sv2 are both type 1 membrane proteins with the same predicted signal peptide, extracellular region, and putative transmembrane domain. However, these proteins have distinct cytoplasmic tails (that of sv1 is longer by Ϸ200 aa) that are nonessential for PA binding, toxin uptake, translocation, or intoxication (ref. 9; K.A.B., G.J.A.R., and J.A.T.Y., unpublished data).
The extracellular domains of ATR͞TEM8 sv1-3 contain a region that is highly related to von Willebrand factor type A domains (VWA domains), also called integrin inserted domains (I domains). VWA͞I domains are well characterized protein interaction sites found in extracellular matrix components or in cell adhesion proteins, like ␣ integrins (reviewed in refs. 13 and 14) . Frequently, VWA͞I domains contain a metal ion-dependent adhesion site (MIDAS; DXDXS. . . T. . . D, where X is any amino acid) that chelates a divalent cation critical for ligand binding (reviewed in ref. 14) . The MIDAS motif of ATR͞TEM8 was recently shown to be essential for the divalent cation-dependent interaction of this receptor with PA (ref. 9 and unpublished results).
Expression of ATR͞TEM8 proteins in a panel of different PA receptor-deficient Chinese hamster ovary (CHO) cell lines restores the sensitivity of these cells to toxin binding (9, 12) . Therefore, it has been proposed that these proteins are the only type of anthrax toxin receptor (12) . However, in this report we identify the human capillary morphogenesis protein 2 (CMG2) as a second anthrax toxin receptor.
CMG2 is the protein most similar to ATR͞TEM8 that has been described to date and has parallel features, which include a signal peptide, type 1 transmembrane region, and a VWA͞I domain (15) . The two protein sequences share 40% overall amino acid identity and 60% identity within their VWA͞I Abbreviations: PA, protective antigen; LF, lethal factor; VWA, von Willebrand factor type A; I, integrin inserted; EGFP, enhanced GFP; CHO, Chinese hamster ovary; sv, splice variant; DTA, diptheria toxin A chain.
domains. CMG2 was originally identified as a gene expressed at elevated levels in human umbilical vein endothelial cells that were induced to undergo capillary formation in threedimensional collagen matrices (15) . Although the precise function of CMG2 is not yet known, its VWA͞I domain binds selectively to collagen type IV and laminin, suggesting that these are its natural ligands in vivo (15) . After using RT-PCR analysis, it was concluded that CMG2 gene expression is restricted to human placental tissue (15) . However, EST data available from NCBI indicate that this gene is expressed in a wide variety of different tissue types (see NCBI UniGene cluster Hs.5897).
Several different CMG2 protein isoforms, encoded by alternatively spliced mRNA transcripts, have been identified or predicted (Fig. 1) . The previously described 386-aa protein is hereafter referred to as CMG2 386 (15) . It has been concluded from f luorescence microscopy studies that the CMG2 386 isoform is expressed predominantly within the endoplasmic reticulum of cells and not at the plasma membrane (15) . In addition, there is an uncharacterized 488-aa isoform of CMG2 (CMG2 488 ) that differs from CMG2 386 in that it includes a 100-aa membrane-proximal region between the VWA͞I domain and transmembrane region and contains 12 alternative amino acids at its C-terminal end. NCBI's ACEMBLY program, which aligns current mRNA and EST data to genomic DNA sequence to predict all possible gene transcript models, indicates that there are two other potential CMG2 protein isoforms that are 322 and 489 aa in length. CMG2 322 is predicted to be a secreted protein without a transmembrane domain, whereas CMG2 489 is identical to CMG2 488 except that its C-terminal 13 aa match those of CMG2 386 (see NCBI's AceView locus 118429; www.ncbi.nlm.nih.gov͞IEB͞Research͞ Acembly͞).
In this article, we have tested whether CMG2 is sufficiently similar to ATR͞TEM8 to function as an anthrax toxin receptor. We show that a CMG2 protein is capable of binding PA in a divalent cation-dependent manner and of supporting intoxication when expressed in a PA receptor-deficient rodent cell line. We also show that a soluble version of the CMG2 VWA͞I domain effectively blocks intoxication of cultured cells. These data show that CMG2 can function as an anthrax toxin receptor and have led to the discovery of a new and potent anthrax antitoxin.
Materials and Methods
DNA Constructs. A 3Ј SMART RACE RT-PCR amplification protocol (CLONTECH) was used to generate cDNA pools from human placental mRNA (CLONTECH). The CMG2 489 ORF (GenBank accession no. AY233452) was isolated multiple times by using nested PCR with CMG2 (GenBank accession no. AY040326) gene-specific oligonucleotide primer sets: 5Ј-GCCACCTTTGCGACCCTCCTGAGCTTAGG-3Ј and 5Ј-TATTTCCCTGCCTCCATTATACTGACTCAAGCAG-3Ј; 5Ј-aactcgagAGGATGGTGGCGGAGCGGTC-3Ј and 5Ј-attagatctccAGCAGTTAGCTCTTTCTCAATACATTCCC-3Ј [CMG2 sequence is indicated with capital letters; restriction sites used to generate the enhanced GFP (EGFP) fusion gene in the murine leukemia virus-based retroviral vector pLEGFP.N1 (CLONTECH) are underlined]. An ATR͞TEM8 sv2-EGFP fusion gene was also cloned in the pLEGFP.N1 and encodes a protein with amino acid residues 1-368 of ATR͞TEM8 (GenBank accession no. NM053034) fused at the BamHI site with EGFP coding sequence. Retroviral vectors were produced by using a previously described transient transfection protocol (9) . A gene encoding CMG2 VWA/I -MycHis with amino acids 1-232 of CMG2 489 was PCR amplified and fused to the MycHis tag in the pcDNA3.1͞myc-His(Ϫ) A vector (Invitrogen) at the HindIII site. All constructs were validated by DNA sequence analysis.
Cell Lines. PA receptor-deficient CHO-R1.1 cells derived from CHO-K1 cells were described elsewhere (9) . CHO-R1.1 cells were infected with retroviral vectors that encoded either CMG2 489 -EGFP or ATR͞TEM8 sv2-EGFP and neomycin phosphotransferase. The transduced cells were then selected in medium containing 900 g͞ml G418, and EGFP-expressing cells were subsequently isolated by flow-cytometric sorting.
Northern Blot Analysis. Northern blot analysis was performed by using a human 12-lane multiple-tissue Northern blot according to the manufacturer's instructions (CLONTECH). The probe used was a 1.5-kb AgeI͞XhoI fragment of pLEGFP.N1-CMG2 489 (corresponding to the full CMG2 489 ORF) labeled by random hexamer priming with [ 32 P]dCTP (Perkin-Elmer). As a control, the blot was also probed with a human ␤-actin probe (CLONTECH). After hybridization, the blot was washed for 30 min at 68°C with 0.5ϫ sodium chloride͞sodium citrate, 0.1% SDS solution.
Purification of CMG2 VWA͞I -MycHis. Forty 10-cm plates of HEK293 cells were transfected with 10 g each of the plasmid vector encoding CMG2 VWA/I -MycHis by calcium phosphate precipitation. Medium was collected 48, 72, and 90 h later, pooled, and purified on an Ni-NTA column (Qiagen, Valencia, CA), and the CMG2 VWA/I -MycHis protein was eluted with 40 mM imidazole. This fraction was dialyzed against Tris-buffered saline (TBS), (B) Four different CMG2 proteins are identified or predicted to result from six alternatively spliced CMG2 mRNA transcripts. CMG2 489 , described in this article, has a putative signal peptide (SP), extracellular VWA͞I domain, and putative transmembrane region (TM). CMG2 488 (GenBank accession no. BAC03731) is identical to CMG2 489 except that the last 12 aa of the cytoplasmic tail diverge (indicated by differences in shading). CMG2 386 (GenBank accession no. AAK77222) is identical to CMG2 489 except that it lacks amino acid residues 213-315. CMG2 322 is predicted to be a secreted protein with amino acid residues 1-290, matching those of CMG2 488 and CMG2 489 but lacking a transmembrane domain (see NCBI's AceView, locus 118429, sv 4 (g).
quantified by using a protein microassay (Bio-Rad), and subjected to electrophoresis on a 12.5% polyacrylamide gel containing SDS, followed by Coomassie blue staining.
PA-Binding Studies. PA binding to CHO-R1.1 cells that expressed CMG2 489 -EGFP or ATR͞TEM8 sv2-EGFP was assessed by flowcytometric analysis; 10 6 cells of each type were incubated with 50 nM PA (1 h, 4°C), washed with PBS, incubated with a polyclonal PA-specific rabbit antiserum (9) (1:500 dilution, 1 h, 4°C), washed with PBS again, and then incubated with an allophycocyaninconjugated anti-rabbit antibody (Molecular Probes; 1:2,000 dilution, 1 h, 4°C). ELISAs were performed by binding 0.3 g of PA83 (List Biological Laboratories, Campbell, CA)͞100 l of TBS in a well of a MaxiSorp plate (Nalge). Samples were then treated with TBST solution (TBS containing 3% BSA and 0.05% Tween 20), washed with TBST, and incubated with 0-300 ng of purified CMG2 VWA/I -MycHis͞100 l TBST in the absence or presence of 1 mM MgCl 2 , MnCl 2 , CaCl 2 , or ZnCl 2 . The samples were then washed with TBST and incubated with a horseradish peroxidaseconjugated anti-His antibody (1:2,000 dilution; Santa Cruz Biotechnology). All incubations for ELISAs were performed for 1 h at room temperature. The levels of bound antibody were then measured by using Supersignal ELISA Pico chemiluminescent substrate (Pierce) and a luminometer (Victor V, Wallac). 
Results

CMG2 Protein
Binds PA in a Divalent Cation-Dependent Manner. The VWA͞I domain of ATR͞TEM8 serves as the site for PA binding (9) and is 60% identical to the VWA͞I domain of CMG2 (Fig. 1 A) . To test whether CMG2 can bind PA, an RT-PCR-based approach was used that led to the isolation of the CMG2 489 ORF from human placental mRNA (GenBank accession no. AY233452; Fig. 1B) . We then constructed a recombinant CMG2 489 -EGFP gene that encodes this CMG2 isoform fused to the EGFP to facilitate protein detection.
To test whether CMG2 489 -EGFP was localized to the cell surface and could bind PA, this protein was expressed in a stably transduced population of PA receptor-deficient CHO-R1.1 cells. PA binding was assayed by flow cytometry after incubating these cells with PA, followed by anti-PA serum and an allophycocyanin-conjugated secondary antibody. For control purposes, these experiments were also performed with the parental receptor-deficient CHO-R1.1 cells, CHO-R1.1 cells that expressed a similar ATR͞TEM8 sv2-EGFP fusion protein, and wild-type CHO-K1 cells that express endogenous PA receptors. These studies revealed that cells expressing either the CMG2 or ATR͞TEM8 fusion protein were equally competent for PA binding ( Fig. 2A) . Thus, we concluded that CMG2 489 -EGFP is expressed at the cell surface and can bind PA.
To investigate whether the CMG2 VWA͞I domain, like that of ATR͞TEM8, is capable of binding directly to PA in a divalent cation-dependent manner, a soluble CMG2 VWA/I -MycHis protein was generated. This protein, which consists of amino acids 1-232 of CMG2 489 fused to a C-terminal MycHis tag, was produced in the supernatants of cultured HEK293 cells and was purified by nickel affinity chromatography (see Fig. 4 Inset). This protein was tested in an ELISA for its ability to bind PA, which had been immobilized on wells of a microtiter plate, in the absence or presence of 1 mM MgCl 2 (16) . Cell viability after intoxication was measured by using a commercially available assay (WST-1 assay; Roche Molecular Biochemicals). Cells that expressed CMG2 489 -EGFP or ATR͞TEM8 sv2-EGFP were killed by the toxin at equivalent levels (Fig. 2C) . The level of killing observed with these cells was higher than that seen with CHO-K1 cells (Fig. 2C) , presumably as a result of higher levels of PA-receptor expression (Fig. 2 A) . These data demonstrate that the CMG2 489 protein functions as an anthrax toxin receptor.
CMG2 mRNA Transcripts Are Readily Detectable in a Number of
Different Human Tissue Types. There is conflicting information available on the tissue-specific expression pattern of the CMG2 gene as discussed previously. To address this controversy, a Northern blot containing 1 g of poly(A) ϩ mRNA samples from 12 human tissues (CLONTECH) was hybridized with a radioactively labeled CMG2-specific DNA probe. This analysis revealed three predominant CMG2 mRNA transcripts, estimated to be Ϸ5.1, 3.9, and 3.4 kb in length, with at least one transcript expressed in 10 of the 12 tissues tested ( Fig. 3 ; transcript lengths were determined by using LABWORKS analysis software, Ultraviolet Products, Upland, CA). CMG2 expression was detected in heart, lung, liver, skeletal muscle, peripheral blood leukocyte, placenta, small intestine, kidney, colon, and spleen but not in brain and thymus (Fig. 3) . Although CMG2 mRNA transcripts have been previously reported in brain tissue (see NCBI UniGene cluster Hs.5897), their level is presumably too low to be detected by Northern blot analysis. The observed CMG2 transcripts corresponded in length to those predicted by NCBI's ACEMBLY method to encode CMG2 488 (5.23 kb), CMG2 322 (3.53 kb), and a CMG2 protein unlike the other isoforms in that it is missing the signal peptide, VWA͞I domain, and most of the extracellular region (4.06 kb) (see NCBI's AceView locus 118429). Whether the observed transcripts actually encode these proteins or some other CMG2 isoform and whether the proteins predicted are actually produced have yet to be proven experimentally. Nevertheless, these data show that the CMG2 gene is expressed at readily detectable levels in a variety of different human tissue types. Soluble CMG2 VWA͞I Domain Is a Potent Antitoxin. Previously, it was shown that soluble ATR͞TEM8 VWA͞I domain protein is an antitoxin that can protect cultured cells from intoxication (9) . To test whether a soluble version of the CMG2 VWA͞I domain can function similarly, the CMG2 VWA/I -MycHis protein was tested for its ability to block intoxication of CHO-K1 cells by PA and LF N -DTA. Strikingly, 100% protection of these cells was achieved at concentrations of Ն300 ng͞ml, and 25% protection was observed at a protein concentration of 100 ng͞ml (Fig. 4) . Based on the 60% representation of CMG2 VWA/I -MycHis protein in the preparation (Fig. 4 Inset; LABWORKS analysis software, Ultraviolet Products) and on its predicted molecular mass calculated by amino acid composition (24.6 kDa), the IC 50 of this protein is estimated to be 3.1 Ϯ 0.2 nM (Fig. 4) .
Discussion
In this article, we demonstrate that an EGFP-tagged form of CMG2 489 is expressed at the surface of PA receptor-deficient CHO cells, binds PA, and supports intoxication of these cells by PA and LF N -DTA at levels comparable with that of ATR͞TEM8 sv2 expressed in the same context. The cell-surface localization of this form of CMG2 contrasts with that of another CMG2 isoform (CMG2 386 ), which is restricted to the endoplasmic reticulum (15) . The binding interaction between a soluble version of the CMG2 VWA͞I domain and PA depends on the addition of divalent cations. We also show that the soluble CMG2 VWA͞I domain functions as a potent antitoxin to protect cultured CHO-K1 cells from intoxication by PA and LF N -DTA, presumably by acting as a receptor decoy to prevent PA from binding to cell-surface receptors. In these experiments, the calculated IC 50 of the CMG2 VWA͞I domain is 3.1 nM, which corresponds to effective blocking activity at a 3:1 ratio of inhibitor to PA. Taken together, these data provide compelling evidence that CMG2 is a second anthrax toxin receptor.
The divalent cation specificity of the PA-CMG2 interaction suggests that the MIDAS motif of the receptor is involved in binding PA, although this remains to be formally tested by mutagenesis studies. The MIDAS motif of ATR͞TEM8 has been shown to be , and an intermediate level was observed in the presence of Mg 2ϩ . Although these data indicate that there are likely to be subtle differences between the PA-ATR͞TEM8 and PA-CMG2 interactions, it remains to be seen which of these metal ions is most physiologically relevant in either case.
The data contained in this article confirm that the CMG2 gene is expressed as three predominant mRNA transcripts in 10 of 12 different human tissues tested, including heart, skeletal muscle, and lung. This expression pattern correlates with EST data compiled by NCBI (see NCBI UniGene cluster Hs.5897) but contrasts with the previously reported RT-PCR expression analysis that indicated that expression of this gene was restricted to human placenta (15 . This possibility can be rigorously examined only after the mRNA profiles of this gene have been more thoroughly characterized. In addition, future studies are needed to determine the relative abundance of each of the CMG2 proteins in different human cell types, as protein levels are affected by additional factors such as protein stability.
The CMG2 488 protein predicted to be encoded by one of the observed predominant CMG2 mRNA transcripts (5.23 kb) is also expected to serve as an anthrax toxin receptor. This isoform differs from CMG2 489 only in its C-terminal 12 aa and is likely to be functional because the cytoplasmic tails of ATR͞TEM8 proteins are not important for receptor activity (12) . Although CMG2 386 seems to have a complete VWA͞I domain, it may not function as an anthrax toxin receptor because it has been observed to be localized intracellularly (15) . Based on experiments with ATR͞ TEM8, neither of the CMG2 proteins predicted to be encoded by the 4.06-or the 3.53-kb transcripts (the protein without a VWA͞I domain or the secreted CMG2 322 , respectively) would be predicted to function as a toxin receptor (9, 12) .
The CMG2 and TEM8 genes are both expressed in a diverse range of different human tissue types ( Fig. 3; ref. 9 ). Therefore, it seems highly likely that both types of receptor are relevant for anthrax pathogenesis. With this in mind, it is not yet clear whether lack of expression of one or both of these proteins accounts for the PA receptor-deficient phenotype of certain mutagenized CHO cell lines (9, 12) . Future studies will determine the relative contribution of each receptor to the disease state. 
